Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against SS&C Technologies Holdings, Inc. (NASDAQ: SSNC) on behalf of SS&C Technologies stockholders. Our investigation concerns whether SS&C Technologies has violated the federal securities laws and/or engaged in other unlawful business practices.

Click here to participate in the action.

On June 9, 2020, the investment management technology firm Arcesium LLC (“Arcesium”) sued SS&C in New York federal court, alleging breach of contract and violation of antitrust laws in connection with SS&C and its subsidiary Advent Software Inc.’s (“Advent”) termination of an agreement with Arcesium to sell Advent’s Geneva accounting software.

As reported by Law360, Arcesium’s suit claims that “Advent attempted to ‘to prevent and destroy competition in this industry’ . . . with Advent’s CEO purportedly stating publicly that the company’s goal was to ‘take over the world’ and be ‘the world's dominant platform.’”

On this news, SS&C’s stock price fell sharply, to close at $59.76 per share on June 9, 2020.

If you purchased or otherwise acquired SS&C Technologies shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Melissa Fortunato or Marion Passmore by email at investigations@bespc.com, or telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.

About Bragar Eagel & Squire, P.C.:

Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York and California. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.